Skip to content

Rheumatoid arthritis — overview

TL;DR — RA is systemic autoimmunity expressed most visibly as persistent inflammatory synovitis. In 2020 about 17.6 million people had RA worldwide; demographic growth is projected to raise cases to 31.7 million by 2050 (GBD 2021 RA Collaborators 2023, PMID 37795020). Early diagnosis, methotrexate-centered therapy and repeated treat-to-target adjustment can prevent much structural damage (Grigor 2004, PMID 15262104; Smolen 2023, PMID 36357155). Biologics and JAK inhibitors expand options but introduce infection, cardiovascular, cancer and thrombotic tradeoffs (Ytterberg 2022, PMID 35081280). The frontier is preventing arthritis in autoantibody-positive high-risk states and selecting drugs from tissue biology rather than sequential failure (Rech 2024, PMID 38364841; Humby 2021, PMID 33485455).

Definition and diagnostic anchors

  • RA is clinical inflammatory arthritis, commonly symmetric and involving small joints, with prolonged morning stiffness, swelling and functional loss.
  • The 2010 ACR/EULAR classification score combines joint involvement, rheumatoid factor/ACPA, acute-phase reactants and symptom duration; ≥6/10 classifies definite RA after excluding a better explanation (Aletaha 2010, PMID 20872595).
  • Classification criteria support research and early recognition but do not replace diagnosis; validation cohorts show sensitivity/specificity tradeoffs (Varache 2011, PMID 21572146).
  • Seronegative RA exists. Conversely, positive rheumatoid factor or ACPA without synovitis is not established RA.
  • Ultrasound/MRI can detect subclinical synovitis and erosion, but imaging-driven escalation beyond clinical targets has not shown consistent added outcome benefit (Mandl 2019, PMID 31518423).

Epidemiology and burden

GBD 2021 estimated 17.6 million prevalent cases in 2020, with an age-standardized global prevalence of 208.8 per 100,000; women were affected more often, and prevalence is projected to reach 31.7 million in 2050 (GBD 2021 RA Collaborators 2023, PMID 37795020).

Burden extends beyond joints: pain, fatigue, work loss, infection, osteoporosis, cardiovascular disease and interstitial lung disease contribute. All-cause and cause-specific mortality remain elevated in meta-analysis despite therapeutic advances (Lee 2024, PMID 38918258).

Mechanism sketch

Genetic risk is led by HLA-DRB1 “shared epitope” alleles alongside many immune loci; smoking interacts strongly with seropositive risk. Genetics is informative at population level, not diagnostic for an individual (Dedmon 2020, PMID 32638005).

Loss of tolerance generates ACPA and rheumatoid factor, sometimes years before joint swelling. Mucosal sites in lung, mouth and gut are candidate initiation compartments. Once synovitis develops, T and B cells, macrophages and pathogenic fibroblast states sustain TNF, IL-6 and other signals; osteoclast activation produces erosions (Jang 2022, PMID 35055087).

Clinical RA is therefore an endpoint of heterogeneous trajectories, explaining variable response to the same cytokine blockade.

Treatment landscape

Early treat-to-target care

The target is remission or low disease activity, assessed with validated composite measures and therapy adjusted on a defined schedule. TICORA showed intensive tight control improved disease activity and radiographic outcomes versus routine care (Grigor 2004, PMID 15262104). FIN-RACo showed early aggressive combination DMARD treatment slowed joint damage over five years (Korpela 2004, PMID 15248204).

EULAR 2022 recommends methotrexate plus short-term glucocorticoids initially for most, escalating to a biologic DMARD or JAK inhibitor when response is insufficient, with risk factors shaping choice (Smolen 2023, PMID 36357155). ACR 2021 also prioritizes methotrexate monotherapy for many DMARD-naive patients and minimizes routine glucocorticoid exposure (Fraenkel 2021, PMID 34101376).

Remission definitions were revised in 2022, increasing the patient global assessment threshold from 1 to 2 on a 0–10 scale while preserving stringent control (Studenic 2023, PMID 36274193).

Conventional, biologic and targeted DMARDs

Methotrexate is the anchor because of effectiveness, experience, combination compatibility and cost; monitoring addresses blood counts, liver, kidney, pulmonary symptoms, interactions and reproductive safety. Systematic review catalogs common gastrointestinal/hepatic and less common serious harms (Wang 2018, PMID 30243154).

Infliximab plus methotrexate in ATTRACT established TNF blockade as a structural and clinical advance in methotrexate-inadequate responders (Lipsky 2000, PMID 11096166). Subsequent classes target IL-6 signaling, B cells and T-cell costimulation.

Upadacitinib outperformed abatacept on efficacy endpoints in SELECT-CHOICE but had more serious adverse events, illustrating efficacy–risk tension (Rubbert-Roth 2020, PMID 33053283).

ORAL Surveillance in RA patients aged ≥50 with cardiovascular risk found tofacitinib failed noninferiority to TNF inhibitors for major adverse cardiovascular events and cancers, leading to stronger class warnings and risk-stratified use (Ytterberg 2022, PMID 35081280).

Difficult-to-treat disease and precision

EULAR defines difficult-to-treat RA by failure of multiple mechanisms plus active/progressive or symptomatic disease that remains problematic; noninflammatory pain, damage, adherence and comorbidity must be separated from immune activity (Nagy 2021, PMID 33004335).

R4RA used synovial biopsy classification in anti-TNF inadequate responders; the overall trial compared rituximab with tocilizumab and provided proof that tissue stratification can be embedded in a multicenter trial, though a definitive routine selector was not achieved (Humby 2021, PMID 33485455).

Extra-articular safety

RA-associated interstitial lung disease includes usual interstitial pneumonia and other patterns and can drive mortality; risk is higher with age, smoking, male sex and seropositivity, but screening and drug selection remain debated (Kadura 2021, PMID 34168062).

Cardiovascular risk reflects conventional factors plus inflammation. Infection risk rises with glucocorticoids and immunosuppression; vaccination and latent-infection screening are integral.

Patient-reported pain, fatigue, function, participation and treatment burden can remain high despite low swollen-joint counts and should not be collapsed into inflammation alone (van Tuyl 2016, PMID 27133486).

Prevention frontier

At-risk intervention is now tested directly. ARIAA found abatacept reduced subclinical inflammation and delayed/reduced RA onset during treatment in ACPA-positive individuals with MRI inflammation (Rech 2024, PMID 38364841). APIPPRA/ALTO found that one year of abatacept delayed progression for up to four years, although the arthritis-free-survival difference diminished to 4.9 months (95% CI 0.1–9.6) and post-treatment symptoms no longer differed (Cope 2026, PMID 41576971). Five-year TREAT EARLIER follow-up was null overall for RA onset but found a risk-enriched ACPA-negative subgroup signal, underscoring that eligibility definitions can reverse the apparent conclusion (Mulligen 2026, PMID 42392130).

How to navigate the evidence

  • Establish objective synovitis before applying an RA treatment algorithm.
  • Separate classification, prognosis, activity and treatment-response biomarkers; they are different jobs.
  • Read relative treatment efficacy beside absolute infection, cardiovascular and cancer risk.
  • Interpret old structural-damage cohorts in their treatment era.
  • Treat prevention as a balance of baseline risk, delay, durability, toxicity and overtreatment.
  • Do not equate low CRP with absent inflammation during IL-6 or JAK pathway inhibition.
  • Do not equate persistent pain or fatigue with persistent synovitis.
  • Consider RA-ILD, cardiovascular disease, infection and fracture as outcome domains, not footnotes.
  • Use patient goals and treatment burden alongside composite disease activity.
  • Keep every page at draft until a separate citation-and-claim audit is complete.

Quantified cross-domain anchors

Question Best quantitative anchor What it does not prove
How common is RA? A 67-study synthesis (742,246 cases; 211.6 million controls) estimated prevalence at 0.46% (95% CI 0.39–0.54), but heterogeneity was extreme (I²=99.9%) and the prediction interval was 0.06–1.27% (Almutairi 2021, PMID 33175207). A pooled historical prevalence is not a country-specific current estimate.
How much diagnostic certainty does classification provide? Across 6,816 patients, the 2010 criteria had pooled sensitivity 0.82 (95% CI 0.79–0.84) and specificity 0.61 (0.59–0.64); versus 1987 criteria, sensitivity rose 0.11 while specificity fell 0.04 (Radner 2014, PMID 23592710). Classification performance is not diagnostic accuracy in unselected musculoskeletal pain.
How large is cardiovascular excess? Seventeen cohorts (124,894 patients) gave incidence-rate ratios of 2.10 (95% CI 1.52–2.89) for myocardial infarction and 1.91 (1.73–2.12) for stroke (Meune 2010, PMID 20656636). Observational excess cannot be assigned wholly to inflammation or a particular drug.
How large is psychological comorbidity? Major depressive disorder prevalence was 16.8% (95% CI 10–24) across definitions, while screening thresholds produced estimates from 14.8% to 38.8% (Matcham 2013, PMID 24003249). Different instruments are not interchangeable diagnoses.
Where does economic burden sit? In 72 cost studies, medicines comprised up to 87% of direct costs and indirect costs 39–86% of total costs; hospital-cost share declined over time (p=0.044) (Hsieh 2020, PMID 32245893). Percentages cannot be transported across payers, prices, and labor systems.
Does methotrexate improve survival? Fifteen observational cohorts gave an association with lower all-cause mortality (HR 0.59, 95% CI 0.50–0.71) (Xu 2022, PMID 35671648). Confounding by indication and healthy-adherer effects prevent a causal survival claim.

The central controversy is therefore not whether RA is inflammatory, but how much of any outcome is attributable to active synovitis, accumulated damage, treatment toxicity, comorbidity, or unequal delivery. Molecular heterogeneity is equally concrete: a 79-donor, 314,000-cell synovial atlas resolved six cell-type abundance phenotypes spanning lymphocyte-rich to lymphocyte-poor tissue and linked them to treatment response (Zhang 2023, PMID 37938773). That finding supports biological stratification, but it does not yet show that choosing therapy from a biopsy improves outcomes.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Kay J. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012. (PMID 23221588) Adjacent evidence from classification-and-diagnosis.md
de Pablo P, et al. Imaging tests predicting RA in unclassified arthritis. RMD Open. 2022. (PMID 34782180) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md
van Heemst J, et al. HLA and rheumatoid arthritis. Ann Med. 2014. (PMID 24813459) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md
Perera J, et al. Seropositive and seronegative RA phenotypes, biomarkers and synovium. 2024. (PMID 38727279) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md
Breedveld FC, et al. Appropriate and effective management of rheumatoid arthritis. Rheumatology. 2004. (PMID 15140767) Adjacent evidence from classification-and-diagnosis.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Which autoantibody-positive individuals should receive prevention, and for how long? (Rech 2024, PMID 38364841; Cope 2024, PMID 38364839)
  • Can synovial tissue or blood markers choose a biologic mechanism reproducibly? (Humby 2021, PMID 33485455)
  • Which patients have sufficient cardiovascular/cancer risk to avoid JAK inhibitors? (Ytterberg 2022, PMID 35081280)
  • How should RA-ILD be screened and treated without worsening joint or lung disease? (Kadura 2021, PMID 34168062)
  • When is sustained remission safe for tapering, and which component should be reduced first? (Tascilar 2021, PMID 38297524; van Mulligen 2020, PMID 32482645)

References

  1. GBD 2021 Rheumatoid Arthritis Collaborators Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594-e610. PMID 37795020
  2. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. PMID 15262104
  3. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3-18. PMID 36357155
  4. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-326. PMID 35081280
  5. Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. PMID 38364841
  6. Humby F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305-317. PMID 33485455
  7. Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81. PMID 20872595
  8. Varache S, et al. Diagnostic accuracy of ACR/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort. J Rheumatol. 2011;38:1250-7. PMID 21572146
  9. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  10. Lee YH, et al. All-cause and cause-specific mortality in rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2024;83:314-320. PMID 38918258
  11. Dedmon LE, et al. The genetics of rheumatoid arthritis. Rheumatology (Oxford). 2020;59:2661-2670. PMID 32638005
  12. Jang S, et al. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int J Mol Sci. 2022;23:905. PMID 35055087
  13. Korpela M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. PMID 15248204
  14. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73:1108-1123. PMID 34101376
  15. Studenic P, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2023;75:15-22. PMID 36274193
  16. Wang W, et al. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502-516. PMID 30243154
  17. Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602. PMID 11096166
  18. Rubbert-Roth A, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383:1511-1521. PMID 33053283
  19. Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31-35. PMID 33004335
  20. Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30:210011. PMID 34168062
  21. van Tuyl LH, et al. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016;42:219-37. PMID 27133486
  22. Cope AP, et al. Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2026;8:e171-e180. PMID 41576971
  23. Mulligen EV, et al. Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2026;8:e638-e649. PMID 42392130
  24. Almutairi K, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41:863-877. PMID 33175207
  25. Radner H, et al. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73:114-23. PMID 23592710
  26. Meune C, et al. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253-61. PMID 20656636
  27. Matcham F, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52:2136-48. PMID 24003249
  28. Hsieh PH, et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020;79:771-777. PMID 32245893
  29. Xu J, et al. Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022;55:152031. PMID 35671648
  30. Zhang F, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023;623:616-624. PMID 37938773
  31. Kay J, et al. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51 Suppl 6:vi5-9. PMID 23221588
  32. de Pablo P, et al. Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis. Semin Arthritis Rheum. 2022;52:151919. PMID 34782180
  33. van Heemst J, et al. HLA and rheumatoid arthritis: how do they connect?. Ann Med. 2014;46:304-10. PMID 24813459
  34. Perera J, et al. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13:743. PMID 38727279
  35. Breedveld FC, et al. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004;63:627-33. PMID 15140767
  36. Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849. PMID 38364839
  37. Tascilar K, et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. 2021;3:e767-e777. PMID 38297524
  38. van Mulligen E, et al. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79:1174-1181. PMID 32482645